financetom
World
financetom
/
World
/
Moderna falls on fears new CDC vaccine advisory panel could cloud RSV shot prospects
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Moderna falls on fears new CDC vaccine advisory panel could cloud RSV shot prospects
Jun 13, 2025 5:49 AM

(Reuters) -Moderna's shares fell 2.5% before the bell on Friday, on concerns whether a new CDC advisory panel would back the use of the company's respiratory syncytial virus vaccine in a broader age group.

The RSV shot, mRESVIA, secured U.S. approval on Thursday for expanded use in at-risk adults aged 18 to 59 years, but needs the U.S. Centers for Disease Control and Prevention's recommendation before it is made available for the age group. It is already approved for use in adults aged 60 or older.

The biotech's stock extended its decline into the second session, following the appointment of the new panel late Wednesday. Some of the new appointees have openly expressed anti-vaccine views, including against the mRNA vaccine technology on which Moderna's shots are based.

Earlier this week, Health Secretary Robert F. Kennedy Jr. fired all 17 members of the panel, known as the Advisory Committee on Immunization Practices (ACIP), saying it would "re-establish public confidence in vaccine science" - a move health experts warn could undermine public confidence in available vaccines.

The ACIP advises the CDC on who should get the shots after they are approved by the U.S. Food and Drug Administration.

The panel meeting for Moderna's RSV shot, scheduled for later this month, will be the "first time for investors to see the refreshed ACIP in action and will be important for sentiment in the vaccine sector, which continues to decline in our view," said William Blair analyst Myles Minter.

U.S.-listed shares of GSK and Pfizer fell marginally and those of smaller Novavax were down 1.7% at $7.03 in premarket trade.

The CDC currently recommends Moderna's vaccine for adults aged 75 and older, as well as for at-risk adults aged 60 to 74.

In April, the ACIP recommended the use of approved RSV vaccines in at-risk adults aged 50 to 59. However, the CDC is yet to sign off on the recommendation.

(Reporting by Mariam Sunny in Bengaluru)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Morning bid: A deep breath before 'Liberation Day'
Morning bid: A deep breath before 'Liberation Day'
Mar 31, 2025
A look at the day ahead in European and global markets from Kevin Buckland The deep breath that global markets are taking in the countdown to Donald Trump's Liberation Day tariff announcement looks like it will continue into the European session, with futures there pointing higher. Wall Street's relatively minor respite was magnified in Asia. Some markets such as Hong...
GLOBAL MARKETS-Stocks stabilise, gold hits record before Trump tariff reveal
GLOBAL MARKETS-Stocks stabilise, gold hits record before Trump tariff reveal
Mar 31, 2025
* Bond yields fall, yen gains as safe havens garner demand * Oil eases from 5-week high as traders weigh slowdown risks * Aussie slips ahead of RBA monetary policy decision * Spot gold hits record high at $3,139.78 per ounce By Kevin Buckland TOKYO, April 1 (Reuters) - Asian equities rose on Tuesday following Wall Street's overnight gains, while...
Stocks stabilise, gold hits record before Trump tariff reveal
Stocks stabilise, gold hits record before Trump tariff reveal
Mar 31, 2025
TOKYO (Reuters) - Asian equities rose on Tuesday following Wall Street's overnight gains, while gold hit an all-time peak and Treasury yields fell as markets awaited details of U.S. President Donald Trump's reciprocal tariffs. The Japanese yen strengthened as traditional haven assets drew demand. Meanwhile, the risk-sensitive Australian dollar was under pressure after a soft reading of local retail sales,...
MORNING BID EUROPE-A deep breath before 'Liberation Day'
MORNING BID EUROPE-A deep breath before 'Liberation Day'
Mar 31, 2025
A look at the day ahead in European and global markets from Kevin Buckland The deep breath that global markets are taking in the countdown to Donald Trump's Liberation Day tariff announcement looks like it will continue into the European session, with futures there pointing higher. Wall Street's relatively minor respite was magnified in Asia. Some markets such as Hong...
Copyright 2023-2025 - www.financetom.com All Rights Reserved